FWBI insider filings
First Wave BioPharma, Inc. — 39 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-04-03. Screen FWBI transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for FWBI between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — First Wave BioPharma, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-04-03 | 4 | Romano Sarah — Chief Financial Officer | Sale (S): 75 @ $4.23 | EDGAR |
| 2024-04-03 | 4 | SAPIRSTEIN JAMES — Chairman and CEO, Director | Sale (S): 174 @ $4.23 | EDGAR |
| 2024-03-19 | 4 | Romano Sarah — Chief Financial Officer | Sale (S): 1,120 @ $4.96 | EDGAR |
| 2024-03-19 | 4 | SAPIRSTEIN JAMES — Chairman and CEO, Director | Sale (S): 1,887 @ $4.96 | EDGAR |
| 2024-03-15 | 4 | Syage Jack — President & COO, Director | Grant/award (A): 15,400 · Grant/award (A): 4,920.04 (derivative) | EDGAR |
| 2024-03-15 | 4 | KHOSLA CHAITAN PHD — Director | Grant/award (A): 440 · Grant/award (A): 140.70 (derivative) · Grant/award (A): 52,980 (derivative) | EDGAR |
| 2024-01-17 | 4 | Romano Sarah — Chief Financial Officer | Sale (S): 98 @ $4.20 | EDGAR |
| 2024-01-17 | 4 | SAPIRSTEIN JAMES — Chairman, President and CEO, Director | Sale (S): 166 @ $4.20 | EDGAR |
| 2024-01-04 | 4 | Riddell Alastair — Director | Grant/award (A): 19,633 @ $0 | EDGAR |
| 2024-01-04 | 4 | Coelho Mary Theresa — Director | Grant/award (A): 19,633 @ $0 | EDGAR |
| 2024-01-04 | 4 | BORKOWSKI EDWARD — Director | Grant/award (A): 19,633 @ $0 | EDGAR |
| 2024-01-04 | 4 | CASAMENTO CHARLES J — Director | Grant/award (A): 19,633 @ $0 | EDGAR |
| 2024-01-03 | 4 | Romano Sarah — Chief Financial Officer | Grant/award (A): 12,614 @ $0 · Grant/award (A): 7,000 @ $0 | EDGAR |
| 2024-01-03 | 4 | SAPIRSTEIN JAMES — Chairman, President and CEO, Director | Grant/award (A): 17,660 @ $0 · Grant/award (A): 20,000 @ $0 | EDGAR |
| 2023-10-06 | 4 | Romano Sarah — Chief Financial Officer | Sale (S): 1,676 @ $0.29 | EDGAR |
| 2023-10-06 | 4 | SAPIRSTEIN JAMES — President and CEO, Director | Sale (S): 2,764 @ $0.29 | EDGAR |
| 2023-09-18 | 4 | CASAMENTO CHARLES J — Director | Sale (S): 10 @ $0.43 | EDGAR |
| 2023-09-05 | 4 | CASAMENTO CHARLES J — Director | Sale (S): 6,053 @ $0.30 | EDGAR |
| 2023-07-05 | 4 | Romano Sarah — Chief Financial Officer | Sale (S): 1,977 @ $1.54 | EDGAR |
| 2023-07-05 | 4 | SAPIRSTEIN JAMES — President and CEO, Director | Sale (S): 3,349 @ $1.54 | EDGAR |
| 2023-04-05 | 4 | Romano Sarah — Chief Financial Officer | Sale (S): 1,975 @ $2.50 | EDGAR |
| 2023-04-05 | 4 | SAPIRSTEIN JAMES — President and CEO, Director | Sale (S): 3,347 @ $2.50 | EDGAR |
| 2023-01-05 | 4 | Coelho Mary Theresa — Director | Grant/award (A): 84,745 @ $0 | EDGAR |
| 2023-01-05 | 4 | Romano Sarah — Chief Financial Officer | Grant/award (A): 150,000 @ $0 | EDGAR |
| 2023-01-05 | 4 | Hoffman David Andrew — Director | Grant/award (A): 84,745 @ $0 | EDGAR |
| 2023-01-05 | 4 | Riddell Alastair — Director | Grant/award (A): 84,745 @ $0 | EDGAR |
| 2023-01-05 | 4 | SAPIRSTEIN JAMES — President and CEO, Director | Grant/award (A): 300,000 @ $0 | EDGAR |
| 2023-01-05 | 4 | BORKOWSKI EDWARD — Director | Grant/award (A): 84,745 @ $0 | EDGAR |
| 2023-01-05 | 4 | CASAMENTO CHARLES J — Director | Grant/award (A): 84,745 @ $0 | EDGAR |
| 2022-03-02 | 4 | Romano Sarah — Chief Financial Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2022-01-03 | 4 | Riddell Alastair — Director | Grant/award (A): 34,482 (derivative) @ $0 | EDGAR |
| 2022-01-03 | 4 | Coelho Mary Theresa — Director | Grant/award (A): 34,482 (derivative) @ $0 | EDGAR |
| 2022-01-03 | 4 | Pennington James — CHIEF MEDICAL OFFICER | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2022-01-03 | 4 | Oakes Gregory — Director | Grant/award (A): 34,482 (derivative) @ $0 | EDGAR |
| 2022-01-03 | 4 | Schramm Vern Lee — Director | Grant/award (A): 34,482 (derivative) @ $0 | EDGAR |
| 2022-01-03 | 4 | Schneiderman Daniel H — CHIEF FINANCIAL OFFICER | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-01-03 | 4 | SAPIRSTEIN JAMES — PRES, CEO & CHAIRMAN OF BOARD, Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2022-01-03 | 4 | BORKOWSKI EDWARD — Director | Grant/award (A): 34,482 (derivative) @ $0 | EDGAR |
| 2022-01-03 | 4 | CASAMENTO CHARLES J — Director | Grant/award (A): 34,482 (derivative) @ $0 | EDGAR |
Recent 8-K events — First Wave BioPharma, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-28 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-28 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-10-07 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-07 | 8-K/A | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities | EDGAR |
| 2026-07-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
Registration filings — First Wave BioPharma, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-296288 (S-1) — latest: Amendment (S-1/A), filed 2026-10-06
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=FWBI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs